Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-4/A Registration of securities (foreign)
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 4.1 Exhibit 4.1
- 4.2 Exhibit 4.2
- 5.1 Exhibit 5.1
- 8.1 Exhibit 8.1
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.10 Exhibit 10.10
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 23.2 Exhibit 23.2
Associated filings
- 19 Jul 22 25-NSE Exchange delisting
- 4 Oct 21 EFFECT Notice of effectiveness
- 1 Oct 21 POS AM Prospectus update (post-effective amendment)
- 8 Mar 21 424B3 Prospectus supplement
- 26 Feb 21 EFFECT Notice of effectiveness
- 26 Feb 21 424B3 Prospectus supplement
- 24 Feb 21 F-4/A Registration of securities (foreign) (amended)
- 19 Feb 21 F-4/A Registration of securities (foreign) (amended)
- 16 Feb 21 F-4/A Registration of securities (foreign) (amended)
-
28 Jan 21 F-4/A Registration of securities (foreign) (amended)
- 8 Jan 21 F-4/A Registration of securities (foreign) (amended)
- 25 Nov 20 F-4 Registration of securities (foreign)
LBPSW similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Amendment No.2 to the Registration Statement (No.333-250986) on Form F-4 of 4D pharma plc of our report dated November 25, 2020, relating to the consolidated financial statements of 4D pharma plc, appearing in the Proxy Statement/Prospectus, which is part of this Registration Statement.
We also consent to the reference to our firm under the heading "Experts" in such Proxy Statement/Prospectus.
/s/ RSM US LLP
Boston, MA
January 27, 2021
1